Zydus Lifesciences Ltd., one of India’s leading innovation-driven healthcare companies, has announced an exclusive licensing and commercialisation agreement with RK Pharma Inc., USA for a novel sterile injectable oncology supportive care product developed under the 505(b)(2) regulatory pathway. The partnership strengthens Zydus’ growing presence in the US complex generics and speciality formulations market.

Under the collaboration, RK Pharma will handle manufacturing and supply of the finished dosage form, while Zydus will oversee NDA submission and commercialisation across the US market. The product is expected to be filed with the USFDA in 2026.

Enhancing Safety & Compliance in Oncology Care

The upcoming 505(b)(2)-based formulation has been designed to reduce dosing errors and improve compliance for healthcare professionals—an area of increasing importance in oncology settings where treatment precision is critical. The product targets a sizeable commercial opportunity, with a total addressable market (TAM) of 6.2 million units as per IQVIA MAT September 2025 data.

Leadership Commentary

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, “We are delighted to collaborate with RK Pharma to bring this innovative product to patients in the US. This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care.”

Dr. Ravishanker Kovi, Founder & Executive Chairman, RK Pharma, added, “This novel 505(b)(2) product highlights our advanced capabilities in formulation and sterile injectable manufacturing. Partnering with Zydus — known for its strong regulatory strengths and commercial reach — ensures the timely availability of this therapy to US patients and supports our shared vision of improving access to high-quality healthcare.”

Also read: Merck’s Enlicitide Delivers Antibody-Like Efficacy in a Pill

Strengthening India–US Pharma Collaboration

The agreement underscores growing cross-border partnerships between Indian and US-based pharmaceutical companies, particularly in complex injectables, speciality drugs, and 505(b)(2) development. For Zydus, this deal further expands its US portfolio of speciality and value-added generics, while RK Pharma leverages its strong formulation development expertise.

The upcoming launch is expected to support unmet needs in oncology supportive care, an area witnessing rising therapeutic demand, stricter safety requirements, and increased emphasis on formulation innovation.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!